Reck, Folkert and Bermingham, Alun and Blais, Johanne and Cazarez, Anthony and Colvin, Richard and Dean, Charles and Furegati, Markus and gamboa, Luis and Growcott, Ellena and Li, Cindy and Lopez, Sara and Metzger, Louis and Nocito, Sandro and Ossola, Flavio and Rasper, Dita and Yue, Qin and Phizackerley, Kaci and Shaul, Jacob and Shen, Xiaoyu and Simmons, Robert L and Tang, Dazhi and Tashiro, Kyuto (2019) IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor. ACS infectious diseases. ISSN 23738227

Abstract

Resistance in Gram-negative bacteria to β-lactam drugs is mediated primarily by the expression of β-lactamases, and co-dosing of β-lactams with a β-lactamase inhibitor (BLI) is a clinically proven strategy to address resistance. New β-lactamases that are not impacted by existing BLIs are spreading and creating the need for development of novel broader spectrum BLIs. IID572 is a novel broad spectrum BLI of the diazabicyclooctane (DBO) class that is able to restore the antibacterial activity of piperacillin against piperacillin/tazobactam-resistant clinical isolates. IID572 is differentiated from other DBOs by its broad inhibition of β-lactamases and the lack of intrinsic antibacterial activity.

Item Type:	Article
Keywords:	antibiotic DBOs diazabicyclooctane piperacillin β-lactamase inhibitors
Date Deposited:	14 May 2019 00:45
Last Modified:	14 May 2019 00:45
URI:	https://oak.novartis.com/id/eprint/38466